Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
20 participants
INTERVENTIONAL
2024-06-01
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
D-chiro-inositol and Endometrial Thickness
NCT05283642
Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT04031456
Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility
NCT00650754
How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome
NCT00878124
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
NCT05279560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Patients will undergo 3 months treatment with 1200 mg D-chiro-inositol and 120 mg lactalbumin, than 3 months treatment with 600 mg D-chiro-inositol and 60 mg lactalbumin
D-chiro-inositol and lactalbumin (high dose)
From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
D-chiro-inositol and lactalbumin (low dose)
From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-chiro-inositol and lactalbumin (high dose)
From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
D-chiro-inositol and lactalbumin (low dose)
From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cancer diagnosis
* Atypical endometrial hyperplasia
* Uterine fibroids
* Heavy symptoms requiring pharmacological intervention
* Progestogens treatment in the six months before the study
* Inositol treatment in the six months before the study
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Of Perugia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandro Gerli
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INOSENDO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.